dc.contributor.author | Dunlop, MV | |
dc.contributor.author | Kilroe, SP | |
dc.contributor.author | Bowtell, JL | |
dc.contributor.author | Finnigan, TJA | |
dc.contributor.author | Salmon, DL | |
dc.contributor.author | Wall, BT | |
dc.date.accessioned | 2017-11-10T14:41:56Z | |
dc.date.issued | 2017-10-11 | |
dc.description.abstract | The anabolic potential of a dietary protein is determined by its ability to elicit postprandial rises in circulating essential amino acids and insulin. Minimal data exist regarding the bioavailability and insulinotropic effects of non-animal-derived protein sources. Mycoprotein is a sustainable and rich source of non-animal-derived dietary protein. We investigated the impact of mycoprotein ingestion, in a dose-response manner, on acute postprandial hyperaminoacidaemia and hyperinsulinaemia. In all, twelve healthy young men completed five experimental trials in a randomised, single-blind, cross-over design. During each trial, volunteers consumed a test drink containing either 20 g milk protein (MLK20) or a mass matched (not protein matched due to the fibre content) bolus of mycoprotein (20 g; MYC20), a protein matched bolus of mycoprotein (40 g; MYC40), 60 g (MYC60) or 80 g (MYC80) mycoprotein. Circulating amino acid, insulin and uric acid concentrations, and clinical chemistry profiles, were assessed in arterialised venous blood samples during a 4-h postprandial period. Mycoprotein ingestion resulted in slower but more sustained hyperinsulinaemia and hyperaminoacidaemia compared with milk when protein matched, with overall bioavailability equivalent between conditions (P>0·05). Increasing the dose of mycoprotein amplified these effects, with some evidence of a plateau at 60-80 g. Peak postprandial leucine concentrations were 201 (sem 24) (30 min), 118 (sem 10) (90 min), 150 (sem 14) (90 min), 173 (sem 23) (45 min) and 201 (sem 21 (90 min) µmol/l for MLK20, MYC20, MYC40, MYC60 and MYC80, respectively. Mycoprotein represents a bioavailable and insulinotropic dietary protein source. Consequently, mycoprotein may be a useful source of dietary protein to stimulate muscle protein synthesis rates. | en_GB |
dc.description.sponsorship | The project was sponsored by Marlow Foods Ltd (B. T. W. as grant holder). The University of Exeter (B. T. W.) were responsible for the study design, data collection and analysis, decision to publish and preparation of the manuscript. The private partners have contributed to the project through regular discussion. M. V. D. is supported through the aforementioned grant, S. P. K. is supported from an internal studentship grant in collaboration with Maastricht University. | en_GB |
dc.identifier.citation | Published online 11 October 2017 | en_GB |
dc.identifier.doi | 10.1017/S0007114517002409 | |
dc.identifier.uri | http://hdl.handle.net/10871/30263 | |
dc.language.iso | en | en_GB |
dc.publisher | Cambridge University Press (CUP) / Nutrition Society | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/29017627 | en_GB |
dc.rights.embargoreason | Publisher policy | en_GB |
dc.rights | © The Authors 2017 | en_GB |
dc.subject | MLK20 20 g milk protein | en_GB |
dc.subject | MYC20 20 g mycoprotein | en_GB |
dc.subject | MYC40 40 g mycoprotein | en_GB |
dc.subject | MYC60 60 g mycoprotein | en_GB |
dc.subject | MYC80 80 g mycoprotein | en_GB |
dc.subject | Amino acids | en_GB |
dc.subject | Bioavailability | en_GB |
dc.subject | Insulin | en_GB |
dc.subject | Mycoprotein | en_GB |
dc.subject | Uric acid | en_GB |
dc.title | Mycoprotein represents a bioavailable and insulinotropic non-animal-derived dietary protein source: a dose-response study | en_GB |
dc.type | Article | en_GB |
exeter.place-of-publication | England | en_GB |
dc.description | This is the final version of the article. Available from CUP via the DOI in this record. | en_GB |
dc.identifier.journal | British Journal of Nutrition | en_GB |